Cargando…

Levosimendan benefits critically ill patients with decompensated heart failure assessed with plasma B-type natriuretic peptide (BNP) and LVEF

Detalles Bibliográficos
Autores principales:	McLean, AS, Huang, SJ, Tang, B, Nalos, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3301501/ http://dx.doi.org/10.1186/cc1945

Ejemplares similares

Efficacy of levosimendan in shock
por: McLean, A, et al.
Publicado: (2004)

Levosimendan reduces pulmonary vascular resistance: clinical echocardiographic study
por: Nalos, M, et al.
Publicado: (2004)

B-type natriuretic peptide (NT-proBNP) and thyroid function: study in elderly subjects
por: Mastroianni, S, et al.
Publicado: (2010)

Relationship between B-type natriuretic peptide plasma levels and echocardiography parameters in decompensated chronic heart failure patients treated with levosimendan
por: Ferri, MB, et al.
Publicado: (2006)

Admissional B-type natriuretic peptide is an independent predictor of outcome in patients with decompensated heart failure
por: Villacorta, H, et al.
Publicado: (2003)

Levosimendan improves hemodynamic effects in patients with acutely decompensated heart failure: the Argentinean multicenter registry
por: Perrone, SV, et al.
Publicado: (2003)

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010)

Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)
por: Maries, Lorena, et al.
Publicado: (2013)

Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies
por: Pereira-Barretto, AC, et al.
Publicado: (2003)

The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure
por: Michalopoulou, H, et al.
Publicado: (2007)

Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with differsent blood BNP levels
por: Pan, Hai-Yan, et al.
Publicado: (2014)

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
por: Bouwer, Nathalie I., et al.
Publicado: (2019)

Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
por: Xiangli, Shen, et al.
Publicado: (2021)

Prognostic value of B-type natriuretic peptide (BNP) and its potential role in guiding fluid therapy in critically ill septic patients
por: Zhang, Zhongheng, et al.
Publicado: (2012)

The utility of B-type natriuretic peptide in differentiating decompensated heart failure from lung disease in patients presenting to the emergency department with dyspnea
por: Villacorta, H, et al.
Publicado: (2003)

Pregnancy-specific Reference Intervals for BNP and NT-pro BNP—Changes in Natriuretic Peptides Related to Pregnancy
por: Dockree, Samuel, et al.
Publicado: (2021)

Science review: Natriuretic peptides in critical illness
por: Witthaut, Rochus
Publicado: (2004)

Association of Repetitive Dosing of Levosimendan with Reduction of NYHA Class and NT-proBNP Levels in Decompensated Heart Failure: A Retrospective Cohort Study
por: Wechsler, Maximilian, et al.
Publicado: (2022)

Levosimendan use in the emergency management of decompensated peripartum cardiomyopathy
por: Uriarte-Rodríguez, Alina, et al.
Publicado: (2010)

Newer treatments for decompensated heart failure: focus on levosimendan
por: Follath, Ferenc
Publicado: (2009)

Levosimendan in Critical Illness: A Literature Review
por: Pierrakos, Charalampos, et al.
Publicado: (2014)

Multiorgan Drug Action of Levosimendan in Critical Illnesses
por: Pan, Jian, et al.
Publicado: (2019)

Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure
por: Noveanu, Markus, et al.
Publicado: (2011)

Point of care with serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) for heart failure in patients with acute decompensation. An invited commentary
por: Sergi, Consolato M.
Publicado: (2022)

Brain Natriuretic Peptide (BNP) and N-Terminal-proBNP in Cardio-Renal Anemia Syndrome　― Difference in Prognostic Ability ―
por: Otaki, Yoichiro, et al.
Publicado: (2019)

Transcriptional reprogramming of metabolic pathways in critically ill patients
por: Nalos, Marek, et al.
Publicado: (2016)

Levosimendan in critically ill adults: a utilisation review
por: Aron, J, et al.
Publicado: (2013)

Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels
por: Valle, Roberto, et al.
Publicado: (2011)

The virtually mature B‐type natriuretic peptide (BNP1‐32) is a precursor for the more effective BNP1‐30
por: Schwiebs, Anja, et al.
Publicado: (2020)

Preoperative NT-proBNP and LVEF for the prediction of acute kidney injury after noncardiac surgery: a single-centre retrospective study
por: Wang, Jiaqi, et al.
Publicado: (2022)

Myocardial efficiency during levosimendan infusion
por: Voipio-Pulkki, L-M, et al.
Publicado: (2002)

Brain natriuretic peptide in acute brain diseases
por: Špatenková, V, et al.
Publicado: (2003)

Determinants of natriuretic peptides in early septic shock
por: Witthaut, R, et al.
Publicado: (1998)

Natriuretic peptides and cGMP in metabolic disease
por: Collins, Sheila
Publicado: (2015)

A Novel Bioassay for the Activity Determination of Therapeutic Human Brain Natriuretic Peptide (BNP)
por: Yu, Lei, et al.
Publicado: (2012)

Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease
por: Khaki, Zohreh, et al.
Publicado: (2022)

Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
por: Juguet, William, et al.
Publicado: (2020)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
por: Nishikimi, Toshio, et al.
Publicado: (2022)

Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP – A narrative review
por: Kerr, Brian, et al.
Publicado: (2022)

Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and other natriuretic peptide forms
por: Takashio, Seiji, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o71hq5umdrl0oc4j3f74d02a17